Pharmaceutical

FDA expands GSK’s Jemperli approval for endometrial cancer

GSK announced that Jemperli plus chemotherapy has obtained expanded FDA approval for primary advanced or recurrent endometrial cancer.

Aug 3, 2024 - 04:00
FDA expands GSK’s Jemperli approval for endometrial cancer
GSK announced that Jemperli plus chemotherapy has obtained expanded FDA approval for primary advanced or recurrent endometrial cancer.
Read the original article

Tags:

Previous Article

Sanofi invests $1.4bn in insulin production in Germany

Next Article

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Under protest, FDA to convene advisory panel to review controversial cell therapy for ALS

STAT+: Under protest, FDA to convene advisory panel to ...

Mar 28, 2023

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Oct 18, 2024

Kaiser Permanente workers announce an official strike date

Kaiser Permanente workers announce an official strike date

Sep 26, 2023